[Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure].
Year: 2013
Type: article
Abstract: The mineralocorticoid receptor antagonists spironolactone and eplerenone have become part of standard medical therapy for heart failure (HF). Randomized clinical trials have shown the clinical efficacy of spironolactone and eplerenone, which lead to lower death rates in patients with systolic HF. Whether these two drugs are equivalent and able to exert a positive effect in patients with clinical HF, including chronic HF with retained left ventricular systolic function remains to be answered.
Source: PubMed
Authors: S N Tereshchenko, I V Zhirov, Iu F Osmolovskaia
Institution: Ministry of Health of the Russian Federation
Language: Russian
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2279875401